Merging bioresponsive release of insulin-like growth factor I with 3D printable thermogelling hydrogels

J Control Release. 2022 Jul:347:115-126. doi: 10.1016/j.jconrel.2022.04.028. Epub 2022 May 6.

Abstract

3D printing of biomaterials enables spatial control of drug incorporation during automated manufacturing. This study links bioresponsive release of the anabolic biologic, insulin-like growth factor-I (IGF-I) in response to matrix metalloproteinases (MMP) to 3D printing using the block copolymer of poly(2-methyl-2-oxazoline) and thermoresponsive poly(2-n-propyl-2-oxazine) (POx-b-POzi). For that, a chemo-enzymatic synthesis was deployed, ligating IGF-I enzymatically to a protease sensitive linker (PSL), which was conjugated to a POx-b-POzi copolymer. The product was blended with the plain thermogelling POx-b-POzi hydrogel. MMP exposure of the resulting hydrogel triggered bioactive IGF-I release. The bioresponsive IGF-I containing POx-b-POzi hydrogel system was further detailed for shape control and localized incorporation of IGF-I via extrusion 3D printing for future applications in biomedicine and biofabrication.

Keywords: 3D printing; Biofabrication; IGF-I; Matrix metalloproteinase; POx; Poly(2-methyl-2-oxazoline)-b-poly(2-propyl-2-oxazine); Transglutaminase.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biocompatible Materials / metabolism
  • Hydrogels* / metabolism
  • Insulin-Like Growth Factor I*
  • Matrix Metalloproteinases / metabolism
  • Polymers
  • Printing, Three-Dimensional

Substances

  • Biocompatible Materials
  • Hydrogels
  • Polymers
  • Insulin-Like Growth Factor I
  • Matrix Metalloproteinases